PTPRC and neoplasm: In mice harboring CRC-PM, the addition of Vox to the anti-PD-1 antibody led to a significant reduction of neutrophils (Ly-6G+CD11b+CD45+), total macrophages (CD11b+F4/80+) and M2-like macrophages (CD11b+F4/80+CD206+) within the tumor mass, compared with the anti-PD-1 antibody alone (figure 3A).